Preliminary results from phase 2 of CC-92480-MM-001: Mezigdomide plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Popat, Rakesh [1 ]
Richardson, Paul G. [2 ]
Trudel, Suzanne [3 ]
Quach, Hang [4 ]
Lonial, Sagar [5 ]
Orlowski, Robert Z. [6 ]
Kim, Kihyun [7 ]
Mateos, Maria-Victoria [8 ]
Pawlyn, Charlotte [9 ,10 ]
Ramasamy, Karthik [11 ]
Martinez-Lopez, Joaquin [12 ]
Casas-Aviles, Ignacio [13 ]
Spirli, Alessia [14 ]
Gong, Jing [15 ]
Amatangelo, Michael [15 ]
Katz, Jessica [15 ]
Maciag, Paulo [15 ]
Peluso, Teresa [14 ]
Bahlis, Nizar J. [16 ]
机构：
[1] Univ Coll London Hosp NHS Fdn Trust, NIHR UCLH Clin Res Facil, London, England
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Univ Toronto, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Univ Melbourne, St Vincents Hosp Melbourne, Melbourne, Australia
[5] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[7] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea
[8] Univ Hosp Salamanca, IBSAL, Salamanca, Spain
[9] Royal Marsden NHS Fdn, London, England
[10] Inst Canc Res, London, England
[11] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford, England
[12] Univ Complutense Madrid, Hosp Octubre, Hosp 12 Octubre, Dept Hematol,CIBERONC, Madrid, Spain
[13] Hosp San Pedro Alcantara, Caceres, Spain
[14] Celgene Int Sarl Bristol Myers Squibb Co, Boudry, Switzerland
[15] Bristol Myers Squibb, Princeton, NJ USA
[16] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH23-PO15
引用
收藏
页码：66 / 67
页数：2
相关论文
共 50 条
  • [1] Mezigdomide (MEZI) monotherapy in relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-001 trial
    Goldsmith, Scott
    Oriol, Albert
    Anttila, Pekka
    Bahlis, Nizar
    Berdeja, Jesus
    Cowan, Andrew
    Dimopoulos, Meletios
    Foster, Laahn
    Hillengass, Jens
    Louzada, Martha
    Wu, Ka Lung
    Chow, Tracy
    Chen, Wencong
    Wang, Yue
    Spirli, Alessia
    Koo, Phillip
    Maciag, Paulo
    Zhu, Daniel
    Katz, Jessica
    Richardson, Paul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S181 - S182
  • [2] Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial
    Orlowski, Robert Z.
    Bahlis, Nizar J.
    Quach, Hang
    Popat, Rakesh
    Lonial, Sagar
    Kim, Kihyun
    Mateos, Maria-Victoria
    Pawlyn, Charlotte
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Casas-Aviles, Ignacio
    Spirli, Alessia
    Gong, Jing
    Amatangelo, Michael
    Katz, Jessica
    Maciag, Paulo
    Peluso, Teresa
    Richardson, Paul G.
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S492 - S493
  • [3] Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
    Richardson, Paul G.
    Trudel, Suzanne
    Quach, Hang
    Popat, Rakesh
    Lonial, Sagar
    Orlowski, Robert Z.
    Kim, Kihyun
    Mateos, Maria-Victoria
    Pawlyn, Charlotte
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Spirli, Alessia
    Casas-Aviles, Ignacio
    Gong, Jing
    Amatangelo, Michael
    Katz, Jessica
    Maciag, Paulo
    Peluso, Teresa
    Bahlis, Nizar J.
    BLOOD, 2022, 140 : 1366 - 1368
  • [4] Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
    Oriol, Albert
    Sandhu, Irwindeep
    Raab, Marc
    White, Darrell
    LeBlanc, Richard
    Raje, Noopur
    Ocio, Enrique
    Perrot, Aurore
    Facon, Thierry
    Rodriguez, Cesar
    Waesch, Ralph
    Amatangelo, Michael
    Zhou, Zehua
    Wang, Yue
    Civardi, Tiziana
    Koo, Philip
    Maciag, Paulo
    Zhu, Daniel
    Katz, Jessica
    Richardson, Paul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S31 - S31
  • [5] Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial
    Oriol, Albert
    Sandhu, Irwindeep
    Raab, Marc S.
    White, Darrell
    LeBlanc, Richard
    Raje, Noopur
    Ocio, Enrique M.
    Perrot, Aurore
    Facon, Thierry
    Rodriguez, Cesar
    Waesch, Ralph
    Amatangelo, Michael
    Zhou, Zehua
    Wang, Yue
    Civardi, Tiziana
    Koo, Phillip
    Maciag, Paulo
    Zhu, Daniel
    Katz, Jessica
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S566 - S566
  • [6] Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial
    Richardson, Paul G.
    Sandhu, Irwindeep
    Hofmeister, Craig C.
    Orlowski, Robert Z.
    White, Darrell
    Belotti, Angelo
    Hansen, Charlotte Toftmann
    Raje, Noopur S.
    Chow, Tracy T.
    Zhou, Zehua
    Civardi, Tiziana
    Koo, Phillip
    Zhu, Yue
    Katz, Jessica
    Oriol, Albert
    BLOOD, 2023, 142
  • [7] Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
    Raab, Marc S.
    Oriol, Albert
    Sandhu, Irwindeep
    White, Darrell
    Leblanc, Richard
    Raje, Noopur
    Ocio, Enrique M.
    Perrot, Aurore
    Facon, Thierry
    Rodriguez, Cesar
    Waesch, Ralph
    Amatangelo, Michael
    Zhou, Zehua
    Wang, Yue
    Civardi, Tiziana
    Koo, Phillip
    Maciag, Paulo
    Zhu, Daniell
    Katz, Jessica
    Richardson, Paul G.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 115 - 115
  • [8] Initial results of phase 1/2 study CC-92480-MM-002 onCELMoD CC-92480 in combination with bortezomib (BORT)and dexamethasone (DEX) in patients with relapsed /refractory multiple myeloma (RRMM)
    Raab, M. -S.
    Richardson, P. G.
    Ocio, E. M.
    Raje, N.
    Gregory, T.
    White, D.
    Oriol, A.
    Sandhu, I.
    LeBlanc, R.
    Rodriguez Valdes, C.
    Trudel, S.
    Waesch, R.
    Perrot, A.
    Bahlis, N. J.
    Zhou, Z.
    Lamba, M.
    Amatangelo, M.
    Civardi, T.
    Katz, J.
    Maciag, P.
    Peluso, T.
    Dimopoulos, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 86 - 86
  • [9] Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Richardson, P. G.
    Trudel, S.
    Popat, R.
    Mateos, M-, V
    Vangsted, A. J.
    Ramasamy, K.
    Martinez-Lopez, J.
    Quach, H.
    Orlowski, R. Z.
    Arnao, M.
    Lonial, S.
    Karanes, C.
    Pawlyn, C.
    Kim, K.
    Oriol, A.
    Berdeja, J. G.
    Rodriguez Otero, P.
    Casas-Aviles, I
    Spirli, A.
    Poon, J.
    Li, S.
    Gong, J.
    Wong, L.
    Lamba, M.
    Pierce, D. W.
    Amatangelo, M.
    Peluso, T.
    Maciag, P.
    Katz, J.
    Pourdehnad, Michael
    Bahlis, Nizar J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (11): : 1009 - 1022
  • [10] Mezigdomide (MEZI; CC-92480) in Combination with Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Raab, M. S.
    Richardson, P. G.
    Sandhu, I
    Oriol, A.
    White, D.
    LeBlanc, R.
    Perrot, A.
    Ocio, E. M.
    Raje, N.
    Hansen, C. Toftmann
    Zhou, Z.
    Civardi, T.
    Katz, J.
    Peluso, T.
    Dimopoulos, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 56 - 56
12345